GGrantIndex
← Leaderboards

Henry Masur

Clinical Center

$938,316
Attributed
$1,901,323
Total exposure
2
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $675.4K · FY201517
$1M$750K$500K$250K$0
'15
'16
'17

Funding mix

By agency

NIH$1,901,323 · 2

By mechanism

U01$1,901,323 · 2

Top collaborators

Most similar at Clinical Center

Same institution · by research overlap

Others in their field

Top investigators on “United States National Institutes Of Health

Research focus

United States National Institutes Of HealthEnrollmentProtocols DocumentationHepatitis CPharmaceutical PreparationsHiv InfectionsNational Institute Of Allergy And Infectious DiseaseUniversitiesHepatitis C VirusHiv/HcvBaseClinical TrialsAcquired Immunodeficiency SyndromeSiteResearch PersonnelAffectInfectionComorbidityCollaborationsFundingSafetyDesignHuman SubjectWashington

Grant awards (100)

Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2025 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2025 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2024 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2024 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2024 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2023 · CL · contact PI
HIV Cardiac Risk Reduction and CD24Fc (CALIBER)$0
ZIA · FY2023 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2023 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2023 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2022 · CL · contact PI
HIV Cardiac Risk Reduction and CD24Fc (CALIBER)$0
ZIA · FY2022 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2022 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2022 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2021 · CL · contact PI
HIV Cardiac Risk Reduction and CD24Fc (CALIBER)$0
ZIA · FY2021 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2021 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2021 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities (SEARCH)$0
ZIA · FY2020 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2020 · CL · contact PI
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes after Hepatitis C Eradication (CHROME)$0
ZIA · FY2020 · CL · contact PI
HIV Cardiac Risk Reduction and CD24Fc (CALIBER)$0
ZIA · FY2020 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2020 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2019 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2019 · CL · contact PI
Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities$0
ZIA · FY2019 · CL · contact PI
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes after Hepatitis C Eradication (CHROME)$0
ZIA · FY2019 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2018 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2018 · CL · contact PI
Sofosbuvir/Ledipasvir for Hep C Rx in HIV/HCV Pre and Post Liver Transplant Subjects$0
ZIA · FY2018 · CL · contact PI
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes after Hepatitis C Eradication (CHROME)$0
ZIA · FY2018 · CL · contact PI
Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant$621,488
U01 · FY2017 · AI
Sofosbuvir/Ledipasvir for Hep C Rx in HIV/HCV Pre and Post Liver Transplant Subjects$0
ZIA · FY2017 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2017 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2017 · CL · contact PI
Study Of Control Of Cytosolic Phospholipase A2 Activity$0
ZIA · FY2017 · CL · contact PI
Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant$604,473
U01 · FY2016 · AI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2016 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2016 · CL · contact PI
Study Of Control Of Cytosolic Phospholipase A2 Activity$0
ZIA · FY2016 · CL · contact PI
Sofosbuvir/Ledipasvir for Hep C Rx in HIV/HCV Pre and Post Liver Transplant Subjects$0
ZIA · FY2016 · CL · contact PI
Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant$601,291
U01 · FY2015 · AI
Single chain urokinase plasminogen activator (scuPA) for treatment of loculated complicated parapneumonic effusions and empyema$74,071
U01 · FY2015 · HL
Study Of Control Of Cytosolic Phospholipase A2 Activity$0
ZIA · FY2015 · CL · contact PI
Sofosbuvir/Ledipasvir for Hep C Rx in HIV/HCV Pre and Post Liver Transplant Subjects$0
ZIA · FY2015 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2015 · CL · contact PI
Neurovascular MRI in the Assessment of HIV-Associated Neurocognitive Disorders$0
ZIA · FY2015 · CL · contact PI
Analysis of Stored Samples Collected Using Previously Expired Protocols$0
ZIA · FY2015 · CL · contact PI
Hemolysis, NO, and PAH in Malaria$0
ZIA · FY2015 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2014 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose Pneumocystis Pneumonia$0
ZIA · FY2014 · CL · contact PI
Hemolysis, NO, and PAH in Malaria$0
ZIA · FY2014 · CL · contact PI
Study Of Control Of Cytosolic Phospholipase A2 Activity$0
ZIA · FY2014 · CL · contact PI
Hemolysis, NO, and PAH in Malaria$0
ZIA · FY2012 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose Pneumocystis Pneumonia$0
ZIA · FY2012 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2012 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose Pneumocystis Pneumonia$0
ZIA · FY2010 · CL · contact PI
Severe Acute Respiratory Syndrome$0
ZIA · FY2010 · CL · contact PI
DC Partnership for HIV/AIDS Progress (DC PFAP)$0
ZIA · FY2010 · CL · contact PI
Hemolysis, NO, and PAH in Malaria$0
ZIA · FY2010 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose Pneumocystis Pneumonia$0
ZIA · FY2009 · CL · contact PI
Severe Acute Respiratory Syndrome$0
ZIA · FY2009 · CL · contact PI
Magnetic Resonance Imagery Study Of Avascular Necrosis Of The Hip In Asymptomati$0
ZIA · FY2009 · CL · contact PI
Evaluation of Endothelial Function in HIV Associated PAH$0
ZIA · FY2009 · CL · contact PI
Hemolysis, NO, and PAH in Malaria$0
ZIA · FY2009 · CL · contact PI
Severe Acute Respiratory Syndrome$0
Z01 · FY2008 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose Pneumocystis Pneumonia$0
Z01 · FY2008 · CL · contact PI
Global initiative to characterize antiretroviral pharmacokinetics$0
Z01 · FY2008 · CL · contact PI
Magnetic Resonance Imagery Study Of Avascular Necrosis Of The Hip In Asymptomati$0
Z01 · FY2008 · CL · contact PI
Study To Assess The Utility Of Oral Washes To Diagnose P$0
Z01 · FY2006 · CL · contact PI
Endothelial Function in Normal Volunteers$0
Z01 · FY2006 · CL · contact PI
Severe Acute Respiratory Syndrome$0
Z01 · FY2006 · CL · contact PI
West Nile Disease$0
Z01 · FY2006 · CL · contact PI
Endothelial Dysfunction as a Risk Factor in HIV$0
Z01 · FY2006 · CL · contact PI
Endothelial Function in Normal Volunteers$0
Z01 · FY2005 · CL
Severe Acute Respiratory Syndrome$0
Z01 · FY2005 · CL
West Nile Disease$0
Z01 · FY2005 · CL
Endothelial Dysfunction as a Risk Factor in HIV$0
Z01 · FY2005 · CL
Magnetic Resonance Imagery Study Of Avascular Necrosis O$0
Z01 · FY2005 · CL
The Utility-Oral Washes-Diagnose Pneumocytis Pneumonia$0
Z01 · FY2005 · CL
Study To Assess The Utility Of Oral Washes To Diagnose P$0
Z01 · FY2004 · CL
Severe Acute Respiratory Syndrome$0
Z01 · FY2004 · CL
Endothelial Function in Normal Volunteers$0
Z01 · FY2004 · CL
West Nile Disease$0
Z01 · FY2004 · CL
Endothelial Dysfunction as a Risk Factor in HIV$0
Z01 · FY2004 · CL
Magnetic Resonance Imagery Study Of Avascular Necrosis O$0
Z01 · FY2004 · CL
Magnetic Resonance Imagery Study Of Avascular Necrosis O$0
Z01 · FY2003 · CL
Severe Acute Respiratory Syndrome$0
Z01 · FY2003 · CL
West Nile Disease$0
Z01 · FY2003 · CL
Endothelial Dysfunction as a Risk Factor in HIV$0
Z01 · FY2003 · CL
Study To Assess The Utility Of Oral Washes To Diagnose P$0
Z01 · FY2003 · CL
Study To Assess The Utility Of Oral Washes To Diagnose P$0
Z01 · FY2002 · CL
Magnetic Resonance Imagery Study Of Avascular Necrosis O$0
Z01 · FY2002 · CL
Study Of Salvage Regimens For Patients With Hiv Infectio$0
Z01 · FY2002 · CL
Magnetic Resonance Imagery Of Hip Avascular Necrosis$0
Z01 · FY2001 · CL
Study Of Salvage Regimens For Patients With Hiv$0
Z01 · FY2001 · CL
Study Of Antiretroviral Pharmacokinetics In Patients Fro$0
Z01 · FY2001 · CL
Study To Assess The Utility Of Oral Washes To Diagnose P$0
Z01 · FY2001 · CL
Magnetic Resonance Imagery Study of Avascular Necrosis of the Hip in Asymptomati$0
Z01 · FY2000 · CL
Study of Salvage Regimens for Patients with HIV Infection Demonstrating Virologi$0
Z01 · FY2000 · CL
Study to Assess the Utility of Oral Washes to Diagnose Pneumocystis Pneumonia$0
Z01 · FY2000 · CL